[1] LAURIE L. BAGGIO Daniel J D. Biology of Incretins: GLP-1 and GIP[J]. Gastroenterology, 2007, 132 6: Pages 2131-2157. DOI:
10.1053/j.gastro.2007.03.054[2] DAVID VAUDRY. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery.[J]. Pharmacological Reviews, 2009, 61 3: 283-357. DOI:
10.1124/pr.109.001370[3] SIMON A HINKE . Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP)[J]. Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 2001, 1547 1: Pages 143-155. DOI:
10.1016/s0167-4838(01)00181-9[4] BARRY D. KERR. Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptide[J]. Biochemical and biophysical research communications, 2011, 404 3: Pages 870-876. DOI:
10.1016/j.bbrc.2010.12.077[5] FINBARR P M O’HARTE. Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice.[J]. American journal of physiology. Endocrinology and metabolism, 2007, 292 6: E1674-82. DOI:
10.1152/ajpendo.00391.2006